Teleflex PT receives Investment Bank Analyst Rating Update
Teleflex (NYSE:TFX) reported Q2 EPS of $3.39, $0.05 better than the analyst estimate of $3.34. Revenue for the quarter came in at $704.5 million versus the consensus estimate of...
Investing.com – U.S. stocks were higher after the close on Wednesday, as gains in the Consumer Goods, Basic Materials and Consumer Services sectors led shares higher. At the close...
Analyst ratings are an imperfect science. However, they do reflect the sentiment of individuals who have significant knowledge of a company’s operations. Ratings are done on...
Investors interested in high returns can choose mid-cap funds that bear lesser risk than small-cap funds. Mid-cap funds are unfazed by the broader market gyrations. This makes...
Teleflex Incorporated’s (NYSE:TFX) adjusted earnings per share (EPS) from continuing operations of $3.28 for the fourth quarter of 2019 were up 18.4% year over year. The...
Teleflex Incorporated is a provider of medical technology products. The Company primarily designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for common diagnostic and therapeutic procedures in critical care and surgical applications. The Company operates through four segments: Americas, Europe, the Middle East and Africa (EMEA), Asia Pacific (Asia) and Original Equipment Manufacturer and Development Services (OEM). OEM segment designs, manufactures and supplies devices and instruments for other medical device manufacturers. It includes the TFX Medical OEM, TFX OEM, Deknatel and HPC Medical brands, provides custom extrusions, micro-diameter film-cast tubing, diagnostic and interventional catheters, balloons and balloon catheters, film-insulated fine wire, coated mandrel wire, conductors, sheath/dilator introducers, specialized sutures and performance fibers, bioabsorbable sutures, yarns and resins.